• Illuminant Surgical

  Participated · Seed · Apr 2026

  Illuminant Surgical develops the Skylight platform, which overlays real-time anatomy directly onto a patient to improve procedural precision and streamline workflows. Skylight combines two proprietary technologies: SkinMatch, a non-invasive patient tracking system using adhesive SkinDots and computer vision to align medical images to anatomy in real time; and LightScreen, a depth-adaptive projection system that displays anatomical details on the patient’s skin. The company is led by co-CEOs Dr. James Hu and Eldrick Millares and is based in Los Angeles, CA. Illuminant Surgical recently raised $8.4M in seed funding to accelerate Skylight’s launch. No revenue, user, or prior funding metrics were disclosed in the articles.

• Piccolo Medical

  Led · Grant · Jan 2024

  Piccolo Medical develops the SmartPICC® catheter navigation and tip location system aimed at improving catheter placement, especially for older adults with heart conditions. The company will use a $3 million Commercialization Readiness Pilot (CRP) grant from the National Institute on Aging (NIH) to advance and secure new regulatory approvals for the SmartPICC technology. This CRP award builds on a 2018 Phase II NIH award that supported development and clinical work for the SmartPICC, including a 42-patient, multi-center clinical study of the first-generation system. Piccolo received 510(k) clearance for the SmartPICC System in 2021. The company was spun out of the Theranova medical device incubator in San Francisco and has been funded by private investors as well as Phase I and II NIH grants. No revenue or user metrics were disclosed in the announcement. Piccolo Medical develops catheter guidance and catheter tip‑location technology for vascular access. Its core product is the SmartPICC® catheter tip location and navigation system, which received FDA 510(k) clearance in January 2021. The company intends to use new funding to further develop and commercialize its catheter guidance technology, including a next‑generation SmartPICC® system. Piccolo was spun out of the Theranova medical device incubator and is led by CEO Augustus (Augie) Shanahan. Historically it has been funded by private investors and by Phase I and II grant awards from the National Institute on Aging.

• T3D Therapeutics

  Participated · Equity · Nov 2019

  T3D Therapeutics, based in Research Triangle Park, NC, is a clinical-stage drug development company focused on treatments for Alzheimer’s disease. It is developing T3D-959, an orally administered, brain-penetrating small molecule dual nuclear receptor agonist designed to improve glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders. The company is led by CEO John Didsbury, Ph.D., and CMO Warren Strittmatter, M.D. T3D closed a $15M financing, with a cornerstone investor and support from the National Institute on Aging. The company intends to use the proceeds to begin the Phase 2 PIONEER study of T3D-959, a double-blind, placebo-controlled, parallel-group safety and efficacy trial. PIONEER is expected to initiate patient dosing in early 2020 and to enroll up to 256 adults with mild-to-moderate Alzheimer’s disease (MMSE 16–26) who will receive one of three doses or placebo for 24 weeks.

No current team members are available.